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Open access under CC BYThe following series of papers presents an extensive assessment of the Electrically Heated Cigarette
Smoking System EHCSS series-K cigarette vs. conventional lit-end cigarettes (CC) as an example for an
extended testing strategy for evaluation of reduced exposure. The EHCSS produces smoke through elec-
trical heating of tobacco. The EHCSS series-K heater was designed for exclusive use with EHCSS cigarettes,
and cannot be used to smoke (CC). Compared to the University of Kentucky Reference Research cigarette
2R4F and a series of commercial CC, mainstream cigarette smoke of both the non-menthol and menthol-
ﬂavored EHCSS cigarettes showed a reduced delivery of a series of selected harmful and potentially
harmful constituents (HPHC), mutagenic activity determined using the Salmonella typhimurium Reverse
Mutation (Ames) assay, and cytotoxicity in the Neutral Red Uptake Assay. Clinical evaluations conﬁrmed
reduced exposure to HPHC and excretion of mutagenic material under controlled clinical conditions.
Reductions in HPHC exposure were conﬁrmed in a real-world ambulatory clinical study. Potential
biomarkers of cardiovascular risk were also reduced under real-world ambulatory conditions. A modeling
approach, ‘nicotine bridging’, was developed based on the determination of nicotine exposure in clinical
evaluations which indicated that exposure to HPHC for which biomarkers of exposure do not exist would
also be reduced.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
There is an overwhelming medical and scientiﬁc consensus that
cigarette smoking is causally related to lung cancer, heart disease,
emphysema, and other serious diseases in smokers (US Depart-
ment of Health and Human Services, 2010). There is no ‘safe’ ciga-
rette and the best way for smokers to reduce the adverse health
consequences of smoking is to quit.
For many years the public health communities’ primary goal
with respect to tobacco control has focused on reducing initiation,
encouraging smoking cessation, and preventing relapse. There has
been a growing interest in recent years, however, in alternative ap-
proaches including that of harm reduction (Gori, 1980; Institute of
Medicine, 2001, 2012; Rodu and Godshall, 2006; Sweanor et al.,
2007; Hatsukami et al., 2007; World Health Organization, 2007;
Royal College of Physicians and Surgeons, 2007; Gilmore et al.,
2009; Zeller et al., 2009; Family Smoking Prevention and Tobacco
Control Act, 2009), stimulated perhaps by the observations that
in spite of the signiﬁcant efforts directed towards tobacco controloducts S.A., PMI Research &
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-NC-ND license.and communication of the risks of smoking, many smokers still
have little interest and/or success in quitting smoking. For exam-
ple, according to the Surgeon General, although about 45% of
smokers quit for a day, only approximately 5% succeed in obtaining
long-term abstinence (US Department of Health and Human Ser-
vices, 2010). The World Health Organization (WHO) Study Group
on Tobacco Product Regulation has deﬁned tobacco harm reduc-
tion as ‘minimizing harms and decreasing total morbidity andmor-
tality, without completely eliminating tobacco and nicotine use’
(World Health Organization, 2007).
Amongst the literature surrounding the questions of harm-
reduced products, much of the focus is on the requirements of an
effective risk evaluation system. A signiﬁcant development in
tobacco control in the US has been the enactment of the Family
Smoking Prevention and Tobacco Control Act (FSPTCA) (Family
Smoking Prevention and Tobacco Control Act, 2009), which
empowers the US Food and Drug Administration (FDA) to evaluate
and regulate Modiﬁed Risk Tobacco Products (MRTPs) (Deyton
et al., 2010). The FSPTCA deﬁnes a MRTP as ‘any tobacco product
that is sold or distributed for use to reduce harm or the risk of
tobacco-related disease associated with commercially marketed
tobacco products.’ The FDA has also been charged to issue guidance
or regulations on the scientiﬁc evidence required for the assess-
ment and ongoing review of MRTPs in consultation with the US
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‘‘Modiﬁed risk Tobacco Product Applications’’ in March 2012 (Food
and Drug Administration, 2012a).
The FSPTCA provides for the approval of an MRTP when reduced
exposure or reduced risk has been demonstrated. Different levels
of evidence are required for these respective approvals, with corre-
spondingly greater ability for communicating product attributes.
The FSPTCA requires applicants to demonstrate that the product,
as actually used, will: (i) signiﬁcantly reduce harm and the risk
of tobacco-related disease to individual tobacco users; and (ii) ben-
eﬁt the health of the population as a whole, taking into account
both users of tobacco products and persons who do not currently
use tobacco products. The FSPTCA’s recognition that harm reduc-
tion now has a statutory place alongside the regulations of food
and medicine provides the platform for moving forward and a
source of conﬁdence that effective, appropriate MRTPs can be
developed and commercialized.
The studies presented in this series of papers were performed
prior to the enactment of the FSPTCA, and publication of the IOM
Report (Institute of Medicine, 2012). At the time, we focused on
evaluating exposure reduction at ‘three levels’: Firstly at the
‘product level’ (i.e., does the product have a reduced yield of a
HPHC under a variety of laboratory conditions), secondly at the
‘individual smoker level’ (i.e., do smokers using these products
experience reductions in their exposure to speciﬁc HPHC), and
ﬁnally at the ‘population level’ (i.e., is this exposure reduction
likely to be realized by both a signiﬁcant proportion of the normal
smoking population given that they are likely to represent a wide
range of ‘actual use’ smoking behaviors). Three considerations
appeared to be essential. Firstly, the product characterization, as
determined in laboratory studies, should not be limited to compar-
isons under standardized smoking conditions but emulate antici-
pated conditions of actual use. Secondly, uptake of relevant
HPHC should be determined in populations that are representative
of those who are most likely to use the product (Hatsukami et al.,
2007, 2012; World Health Organization, 2007). The latter requires
valid biomarkers of exposure as well as selection of appropriate
populations and reference products that can be considered as rea-
sonably representative of those used by smokers who may switch
to using the new products. Thirdly, consideration of the potential
reduction in exposure by non-smokers to environmental aerosols
produced by the MRTP vs. environmental tobacco smoke (ETS)
from a CC must also be investigated. Tricker et al. (2009) has pub-
lished a comparative indoor air quality assessment of EHCSS ser-
ies-K vs. a CC.
Clearly, in consideration of both the Draft Guidance on ‘‘Modi-
ﬁed Risk Tobacco Product Applications’’ (Food and Drug Adminis-
tration, 2012a) and the IOM Report (Institute of Medicine, 2012),
further work is needed in order to meet such a standards. We nev-
ertheless consider that product testing is an iterative process and
the data reported here should be considered as relevant, although
not sufﬁcient, for the evaluation of reduced exposure, reduced risk,
and population harm.
Although the causal relationship between smoking and several
diseases has been well established (Doll et al., 2004), there is still
very little understanding of the underlying mechanisms. More than
5300 chemical compounds have been identiﬁed in cigarette tobac-
co smoke (Rodgman and Perfetti, 2009). Public health authorities
and representatives now propose some 100 HPHC as possible
causes of smoking-related diseases such as lung cancer, heart dis-
ease, and emphysema (Health Canada 2000; Food and Drug
Administration, 2012b; Talhout et al., 2011). There is no consensus,
however, that lowering or eliminating any single compound (or
even a combination of compounds) in smoke would have a signif-
icant impact on risk. Partly in response to this dilemma, the IOM
introduced the concept of a ‘Potential Reduced-Exposure Product’(PREP) (Institute of Medicine, 2001), based on a ﬁrst assumption
that reduction of exposure is related to a reduction in harm.
We have focused on the development of products that substan-
tially reduce or eliminate a wide spectrum of HPHC. Our current
approach achieves this by eliminating direct tobacco combustion
and limiting tobacco pyrolysis by heating at signiﬁcantly lower
temperatures than encountered in CC. However, the IOM and oth-
ers conclude that simply reducing exposure does not necessarily
equate to harm reduction (Institute of Medicine, 2001; World
Health Organization, 2007; Zeller et al., 2009). Thus, a comprehen-
sive assessment of reduced exposure is necessary, but is not sufﬁ-
cient for determining a modiﬁed tobacco product’s potential to
reduce risk. Novel testing strategies have been recently proposed
by the IOM (Institute of Medicine, 2012).
The following series of papers presents an extensive assessment
of the EHCSS series-K cigarette vs. CC as an example for an ex-
tended testing strategy for evaluation of reduced exposure. The
concept of reduced exposure in this testing strategy considers a
broad range of potential smoking behaviors, and characterizes
the potential reductions in exposure to a range of HPHC in cigarette
smoke which could be considered to be of importance in relation to
smoking-related diseases.2. The Electrically Heated Cigarette Smoking System (EHCSS)
Tobacco smoke from CC consists of an aerosol containing liquid
droplets (‘particulate phase’) suspended in the gas–vapor phase. It
is generated by complex and overlapping burning-, pyrolysis-,
pyrosynthesis-, distillation-, sublimation-, and condensation pro-
cesses (Borgerding and Klus, 2005). With minor exceptions, both
pyrogenesis and pyrosynthesis of HPHC result from the thermal
decomposition from organic tobacco compounds taking place at
elevated temperatures (Baker, 2006; Borgerding et al., 1997;
Torikai et al., 2005), thus, a reduction of these toxicants may be
achieved by generating a simpler smoke aerosol, e.g., by heating
rather than burning tobacco (e.g., ECLIPSE Expert Panel, 2000).
The ﬁrst-generation of the EHCSS (series-E) has been subject to
extensive analytical and toxicological evaluation (Patskan and
Reininghaus, 2003) demonstrating simpliﬁed smoke chemistry
compared to the University of Kentucky 1R4F reference research
cigarette (Stabbert et al., 2003) and against a series of CC from
the US (Roemer et al., 2004). The 1R4F cigarette is considered to
be representative of the low ‘tar’ segment of the US cigarette
market (Diana and Vaught, 1990). Notable was the signiﬁcant
reduction in carbon monoxide (CO) and increased yield of formal-
dehyde in EHCSS-E mainstream smoke, compared to the 1R4F cig-
arette. On a per milligram total particulate matter (TPM) basis the
concentration of formaldehyde was increased approximately sev-
enfold (Stabbert et al., 2003). The in vitro genotoxicity and cytotox-
icity of mainstream smoke (Tewes et al., 2003; Roemer et al., 2004;
Schramke et al., 2006) and the biological activity of mainstream
smoke was reduced in a 90-day sub-chronic rat inhalation study,
compared to the 1R4F cigarette (Terpstra et al., 2003). A clinical
evaluation performed in the US conﬁrmed that exposure to se-
lected mainstream cigarette smoke constituents was reduced
(Roethig et al., 2005).
A second-generation EHCSS (series-JLI) was developed in which
ammonium magnesium phosphate (AMP) was used in the ciga-
rette paper to replace calcium carbonate (Fournier and Paine,
2001). It was anticipated that ammonia released during the pyro-
lysis of AMP would condense with formaldehyde to form hexa-
methylenetetramine (HMT). Chemical analysis of smoke from the
EHCSS-JLI cigarettes containing AMP showed lower yields of form-
aldehyde and several reported HPHC, a further decrease in CO
yield, and increased yields of ammonia and HMT (Roemer et al.,
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icity and genotoxicity has been reported in detail (Roemer et al.,
2008). Reduced toxicological activity of mainstream smoke was
also determined in both a 90-day sub-chronic rat inhalation study
and a 35-day study focusing on lung inﬂammation in rats (Moen-
nikes et al., 2008). Clinical evaluations also conﬁrmed reduced
exposure to selected HPHC and reduced excretion of mutagenic
material in urine (Roethig et al., 2007, 2008). Further clinical eval-
uations concluded that switching from CC to the second-genera-
tion EHCSS-JLI cigarette improved prognostic markers for cardiac
disease assessed by symptom-limited spiroergometry (Unverdor-
ben et al., 2007), heart rate and rate-pressure-product parameters
(Unverdorben et al., 2008) after three days of product switching.
The third-generation EHCSS (series-K) electrical heater, which
can be used with EHCSS menthol or non-menthol cigarettes pro-
vides up to 8 puffs per cigarette (Werley et al., 2008). The EHCSS
uses controlled heating of tobacco at a temperature signiﬁcantly
less than encountered in the burning cone of a CC, and CC fail to
activate the electronic system incorporated in the puff-activated
heater. The EHCSS series-K cigarette contains a column of cigarette
tobacco ﬁller, wrapped in a tobacco mat with a cigarette paper
overwrap. EHCSS-K3 and EHCSS-K6 cigarettes differ in the con-
struction of the ﬁlter, with a more efﬁcient ﬁlter being used in
the EHCSS-K3 cigarette (Fig. 1).
The series-K cigarette is characterized by a reduced delivery of
HPHC in mainstream smoke and reductions in several toxicological
endpoints as observed in a battery of in vitro and in vivo assays
(Werley et al., 2008). In addition, virtually eliminating the forma-
tion of sidestream smoke, which is normally formed by the smoul-
dering of a CC, results in signiﬁcantly lower concentrations of ETS
when EHCSS cigarettes are smoked compared to a CC (Frost-Pineda
et al., 2008a; Tricker et al., 2009). Selected biomarkers of exposure
to HPHC have been shown to be reduced in clinical evaluations of
CC smokers who switched to use the EHCSS-K6 cigarette (Frost-
Pineda et al., 2008b,c). Favorable changes towards increased heart
rate variability (Munjal et al., 2009) and pulmonary function
(Unverdorben et al., 2010) have also been observed after switching
from smoking CC to the EHCSS-K6 cigarette for three days.Fig. 1. Representation of the EHCSS3. Testing strategy
The current strategy is based on both non-clinical and clinical
evaluations in which reduced exposure assessment is considered
in a translational approach from ‘product level – to smoker level
– to population level’. The presented strategy is an extension of pre-
vious reduced exposure assessments of the 5 mg ISO tar EHCSS-K6
cigarette (Werley et al., 2008; Frost-Pineda et al., 2008b,c).
A key component of this strategy is the consideration of a range
of machine smoking conditions for the laboratory assessments. It is
known that smoking topography, e.g., puff volume, puff duration,
inter-puff interval, varies greatly among smokers (Schorp, 2005),
and this may explain, in part, the signiﬁcant within- and be-
tween-smoker variability of nicotine uptake and toxicant exposure
(Byrd et al., 1998; Jarvis et al., 2001; Ueda et al., 2002; Scherer
et al., 2007a; Fidler et al., 2008; Mendes et al., 2009; Lindner
et al., 2011). Consequently, we have investigated the performance
of the products under 25 different machine smoking conditions
reﬂective of multiple human smoking topographies. These labora-
tory studies include extensive smoke chemistry analysis in addi-
tion to in vitro assessments.
In addition, we have selected the CC used as comparator/refer-
ence products in the studies (Table 1) based on our understanding
of the type of CC smoked by the populations considered most likely
to switch to the EHCSS series-K cigarette in a number of different
countries. It was considered essential, for example, to ensure that
any reduction in exposure that may be achieved by switching to
the EHCSS would remain valid when compared to exposure result-
ing from using a representative CC with low International Organi-
zation for Standardization (ISO) tar and nicotine yields. With these
considerations in mind, six different CC were selected as bench-
marks that either matched the ISO tar delivery of the EHCSS ser-
ies-K cigarettes or represented the lowest ISO tar delivery of
commercially available cigarettes in the countries in which clinical
evaluations were performed (Table 1).
In selecting the sites for the clinical studies, we chose countries
for which we had reason to believe smoking behavior patterns
might be quite different. There is, for example, a general under--K6 and EHCSS-K3 Cigarettes.
Table 1
Mainstream smoke yields of tar, nicotine and carbon monoxide in EHCSS series-K
cigarettes and comparator market cigarettes.
Cigarette Brand name Tar
[mg/cig.]
Nicotine
[mg/cig.]
CO
[mg/cig.]
EHCSS-K3* – 3 0.2 0.6
EHCSS-K6* – 5 0.3 0.6
EHCSS-K6M* – 5 0.3 0.5
M6UK Marlboro 6 0.5 7
M6J Marlboro 6 0.5 7
M4JM Marlboro Ultra Lights Menthol 4 0.3 5
PM1 Philip Morris One 1 0.2 2
Lark1 Lark One 1 0.1 2
Lark1M Lark One Menthol 1 0.1 2
* Tar, nicotine and carbon monoxide were determined in conformity with Inter-
national Organization for Standardization (ISO) methods. Puff count was set to 8
puffs based on lighter design, and data were obtained when the EHCSS-K was
smoked on a linear smoking machine.
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and taste preferences for mentholated products compared to
smokers in Western Europe (Ueda et al., 2002; Giovino et al.,
2004) while Korea represents a cigarette market in which smokers
have a preference for smoking cigarettes with very low smoking
machine-measured ISO tar and nicotine yields.4. In vitro toxicological assessment of test and marketed
reference cigarettes
In Part 2 of this series of papers (Zenzen et al., 2012), ‘product
level’ testing was performed to determine up to 49 HPHC in main-
stream smoke of EHCSS-K3, EHCSS-K6, EHCSS-K6M and four repre-
sentative CC (M6UK, PM1, M6J, Lark1) according to ISO machine
smoking conditions (International Organization for Standardiza-
tion, 2000). The list of HPHC determined included compounds rec-
ommended by the US Consumer Product Safety Commission (US
Consumer Products safety Commission in Consultation with the
US Department of Health and Human Services, 1993) and evalu-
ated for carcinogenicity (International Agency for Research on Can-
cer, 1987). The list of compounds analyzed included the
determination of all nine HPHC recommended for mandated low-
ering of exposure levels (World Health Organization, 2008). In
addition, smoke chemistry and in vitro toxicological assessment
was performed using 25 different machine-smoking regimens
delivering a range of nicotine yields between the 10th–90th per-
centiles of clinically determined nicotine uptake distributions
(‘Human Pufﬁng Behavior‘ [HPB] regimens). The HPB protocols
for each of the four CC were determined using a modeling ap-
proach (Urban et al., 2008), and a matrix approach was applied
for the EHCSS series-K cigarettes (Zenzen et al., 2012). A subset
of the data set (EHCSS-K6, M6UK, and PM1 cigarettes; ISO regimen
and 15 additional experimental machine-smoking regimens
reﬂecting HPB) was used to develop the ‘nicotine bridging’ method
(Urban et al., 2012). The HPB regimens were used since standard
machine-smoking protocols are not representative of human
smoking behavior and cannot be used to predict the actual expo-
sure of a smoker (Gori and Lynch, 1985).
In vitro toxicological assessment was performed to assess bacte-
rial mutagenicity of the smoke particulate phase (condensate) to-
wards three tester strains of Salmonella typhimurium (TA98,
TA100, and TA1537 with S9 activation) in the Salmonella reverse
mutation assay (Maron and Ames, 1983) according to recommen-
dations by the Organization for Economic Co-operation and Devel-
opment (Organization for Economic Co-operation and
Development, 1997) and International Conference on Harmoniza-
tion (International Conference on Harmonization, 1995). Thesestrains were not used to determine excretion of mutagenic mate-
rial in the urine of smokers in clinical studies (Tricker et al.,
2012a,b,c,d). Instead, the strain YG1024, an O-acetyltransferase-
overproducing derivative of TA98, was used which is more sensi-
tive to the presence of mutagens in urine (Einistö et al., 1990; De
Flora et al., 1995; Kuenemann-Migeot et al., 1997).
Cytotoxicity of both the particulate and the gas–vapor phase of
mainstream smoke were determined by the Neutral Red Uptake
(NRU) assay according to INVITTOX protocol No. 3a (INVITTOX,
1990). The test material was generated using both ISO and HPB
machine-smoking regimens.
These non-clinical evaluations served to address four main
objectives:
 To understand the new product’s potential to reduce exposure
based on reductions in smoke chemistry as compared to CC
using multiple smoking regimen,
 To provide quantitative data to design clinical studies to test
reductions in exposure to selected HPHC in the new product,
 To assess acceptability of the new product for use in human
clinical studies, the minimum criteria of which was to ensure
that the product would not present an increased or new hazard
in comparison to CC, and
 To provide a broad range of measures to characterize the prod-
uct which could not be directly determined in clinical
evaluations.
5. Clinical evaluations
Controlled clinical studies are reported in Parts 3–7 of this ser-
ies of papers (Martin Leroy et al., 2012; Tricker et al., 2012a,b,c,d).
Studies were performed to determine the ‘smoker level’ exposure
to selected HPHC when using test (i.e., EHCSS) and reference (i.e.,
CC) products. In order to substantiate the potential of a new tobac-
co product to reduce the exposure to HPHC, a reliable panel of bio-
markers for assessing exposure in human smokers was used
(World Health Organization, 2008). The panel of biomarkers of
exposure to selected HPHC was selected based on (i) previously
determined smoke chemistry (Part 2; Zenzen et al., 2012), (ii) abil-
ity of the biomarker of exposure to determine differences in expo-
sure of the parent compound in cigarette smoke (Hecht, 2003; Feng
et al., 2006; Carmella et al., 2009; Scherer et al., 2007b), and (iii)
validation of the analytical methods for the determination of the
biomarker in urine according to US FDA guidance (Food and Drug
Administration, 2001). Individual tobacco smoke-speciﬁc and to-
bacco smoke-associated biomarkers of exposure were also selected
depending on the individual study protocols resulting in a panel of
biomarkers for the assessment of exposure to 12 selected HPHC
and excretion of mutagenic material in urine (Table 2).
The panel of biomarkers of exposure included ﬁve of the nine
toxicants (1,3-butadiene, acrolein, benzene, carbon monoxide,
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK]) rec-
ommended for mandated lowering in cigarette mainstream smoke
(World Health Organization, 2008). Of the remaining four smoke
toxicants (acetaldehyde, benzo(a)pyrene, formaldehyde, and N0-
nitrosonornicotine), suitable biomarkers of exposure and/or ana-
lytical methods were not available at the time of the studies. The
panel of biomarkers of exposure included:
 Nicotine and its metabolites since these are well established
tobacco-speciﬁc biomarkers for assessment of exposure to ciga-
rette smoke (Society for Research on Nicotine and Tobacco Sub-
committee on Biochemical Veriﬁcation, 2002; Tricker, 2006). On
a quantitative basis, the determination of the concentration of
the molar sum of nicotine, cotinine, trans-3’-hydroxycotinine,
and their respective glucuronide conjugates, expressed as nico-
Table 2
Summary of smoke constituent and biomarkers of exposure determined in the EHCSS clinical evaluations.
Smoke constituent Biomarker of exposure Country of evaluation
UK Korea Japan Japan Poland
EHCSS-K3/K6 EHCSS-K3 EHCSS-K3/K6 EHCSS-K6M EHCSS-K6
Tricker et al.
(2012a)
Tricker et al.
(2012b)
Tricker et al.
(2012c)
Tricker et al.
(2012d)
Martin Leroy
et al. (2012)
1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) U U U U U
2-Naphthylamine 2-Naphthylamine (2-NA) – U U U U
4-Aminobiphenyl 4-Aminobiphenyl (4-ABP) – U U U U
Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA) U U U U U
Acrylamide Acrylamide mercapturic acid (AAMA) – U U U U
Glycidamide mercapturic acid (GAMA) – U U U U
Benzene S-Phenyl mercapturic acid (S-PMA) U U U U U
Carbon monoxide Carbon monoxide (CO) – – – – U
Carboxyhemoglobin (COHb) U U U U U
Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA) U U U U –
Nicotine Cotinine (COT-P) U U U U –
Nicotine (NIC-P) U U – –
Nicotine equivalents (NEq)b U U U U U
NNKa Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)c U U U U U
Pyrene Total 1-hydroxypyrene (1-OHP)d U U U U U
o-Toluidine o-Toluidine (o-TOL) – U U U U
Mutagens Salmonella mutagenicity (YG1024 with S9) U U U U –
a NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
b Nicotine equivalents (NEq) were determined as the molar sum of nicotine, cotinine, and trans-3’-hydroxycotinine plus their respective glucuronide conjugates.
c Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its O-glucuronide
conjugate.
d Total 1-hydroxypyrene (1-OHP) was determined as the molar sum of 1-hydroxypyrene and its glucuronide and sulfate conjugates.
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approximately 85% of the total nicotine uptake (Benowitz
et al., 1994; Tricker, 2006). In addition, serum cotinine and
plasma nicotine were also determined in some of the clinical
evaluations (Benowitz, 1988).
 Carboxyhemoglobin (COHb) was selected as a biomarker of CO
exposure based on its classical use for determination of tobacco
smoke exposure (Rieben, 1992; Society for Research on Nicotine
and Tobacco Subcommittee on Biochemical Veriﬁcation, 2002;
Scherer, 2006).
 Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
plus its O-glucuronide conjugate 4-[(methylnitrosamino)-1-(3-
pyridyl)but-1-yl]-b-O-D-glucosiduronic acid (NNAL-Gluc) was
determined as a tobacco-speciﬁc biomarker of exposure to
NNK (Hecht and Tricker, 1999).
 Total 1-hydroxypyrene (1-OHP) plus its glucuronide and sulfate
conjugates (Strickland et al., 1996) was determined as a surro-
gate marker for the total concentration of polycyclic aromatic
hydrocarbons (PAHs) present in cigarette smoke (Brandt and
Watson, 2003).
 2-Naphthylamine (2-NA), 4-aminobiphenyl (4-ABP), and o-tolu-
idine (o-TOL) were determined directly in urine (Riedel et al.,
2006) as representative aromatic amines present in cigarette
smoke (Matsuda and Hoffmann, 1969; Patrianakos and Hoff-
mann, 1979).
 N-Acetyl-S-(2-carbamoylethyl)-L-cysteine (AAMA) and N-(R,S)-
acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine (GAMA)
were determined in urine as biomarkers of exposure to acryl-
amide (Urban et al., 2006).
 1-Hydroxy-2-(N-acetylcysteinyl)-3-butene and 1-(N-acetylcy-
steinyl)-2-hydroxy-3-butene (collectively called MHBMA for
monohydroxybutenyl mercapturic acid) were determined in
urine as a biomarker of exposure to 1,3-butadiene (van Sittert
et al., 2000).
 3-Hydroxy-1-methylpropylmercapturic acid (HMPMA) was
determined as a biomarker of exposure to crotonaldehyde, an
a,b-unsaturated aldehyde present in cigarette smoke (Scherer
et al., 2007b). S-Phenyl mercapturic acid (S-PMA) was selected from several
known metabolites of benzene as a biomarker of exposure to
benzene in tobacco smoke (Melikian et al., 1993; Fustinoni
et al., 2005).
 3-Hydroxypropyl mercapturic acid (3-HPMA) was selected as a
biomarker of exposure to acrolein (Mascher et al., 2001).
In addition, Salmonella typhimurium YG1024 was used to deter-
mine excretion of mutagenic material in urine (Einistö et al., 1990).
The clinical studies had one primary objective: To compara-
tively assess exposure reductions of EHCSS vs. CC smoke HPHC,
when these products were used by different smoking populations.
This testing strategy extends the observed differences in smoke
chemistry reductions using standardized machine-smoking proto-
cols (‘product level’), to a measure of actual uptake in a controlled
clinical environment (‘smoker level’), minimizing biases such as
dual use, or differential exposures from other sources. This ap-
proach partially addresses differences in smoking behavior and
exposure to tobacco smoke HPHC, albeit with some limitations.
For example, the circumstances of use within the clinical environ-
ment may be quite artiﬁcial and the maximum actual use level of
the EHCSS (i.e., number of smoked cigarettes per day) was limited
to the determined consumption of CC at Baseline. Thus, subjects
could not increase their use of EHCSS above the number of CC they
had originally smoked, i.e., one possible method for compensation
was, in effect, prohibited by the study design (Scherer, 1999).
In Part 3 of this series of papers, an 8-day randomized, con-
trolled, open-label, parallel-group, single-center study design was
used to compare biomarkers of exposure to nine selected HPHC
in cigarette smoke (Table 2) in 160 male and female Caucasian sub-
jects smoking the M6UK cigarette at baseline who were random-
ized to continue smoking M6UK cigarettes, or switch to EHCSS-
K3, EHCSS-K6, or PM1 cigarettes (for cigarette deﬁnitions see Ta-
ble 1), or to no-smoking (Tricker et al., 2012a). The study was con-
ducted in Belfast, Northern Ireland, The primary objectives of the
study were to compare exposure to benzene and CO between the
study groups on Day 8 vs. baseline (Day 0). The mean decreases
from baseline to Day 8 were statistically signiﬁcant (p 6 0.05) for
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mutagenic material in urine in the EHCSS-K3 (range:
41.2 ± 26.6% to 83.1 ± 9.2% [mean ± standard deviation]) and
EHCSS-K6 (range: 35.5 ± 29.2% to 79.4 ± 14.6%) groups. The
largest reductions in exposure occurred in the no-smoking group
(range: 55.4 ± 45.0% to 100.0 ± 0.0%).
In Part 4 of this series of papers, an 8 day randomized, con-
trolled, open-label, parallel-group, single-center study design was
used to compare biomarkers of exposure to twelve selected HPHC
(Table 2) in urine, in 72 male and female Korean subjects smoking
the Lark1 cigarette at baseline who were randomized to continue
smoking the Lark1 cigarette, or switch to using EHCSS-K3, or to
no-smoking (Tricker et al., 2012b). The study was conducted in
Seoul, South Korea. The primary objective of the study was to com-
pare exposure to CO between the study groups on Day 8. CO expo-
sure was signiﬁcantly lower in the EHCSS-K3 group than in the
Lark1 group at Day 8 (p < 0.001). The mean decreases from baseline
(Day 0) to Day 8 were statistically signiﬁcant (all p < 0.05) for 10 of
12 selected HPHC in mainstream cigarette smoke including CO, in
the EHCSS-K3 group (range: 1.5 [9.9,0.1]% to 74.2 ± 10.1%).
Exposure to acrolein (1.3 ± 35.8%) was not signiﬁcantly reduced,
and exposure to crotonaldehyde was increased (28.1 ± 155.3%).
The largest mean reductions in HPHC occurred in smokers who
switched to no-smoking (3.4 ± 41.8 to 98.9 ± 0.6%). Excretion
of mutagenic material in urine was decreased signiﬁcantly
(p < 0.05) in the EHCSS-K3 and no-smoking groups
(31.8 ± 48.8% and 45.3 ± 29.7%, respectively).
In Part 5 of this series of papers, an 8-day randomized, con-
trolled, open-label, parallel-group, single-center study design to
compare biomarkers of exposure to twelve selected HPHC in ciga-
rette smoke (Table 2) in 128 male and female Japanese subjects
smoking M6J cigarettes at baseline who were randomized to con-
tinue smoking M6J cigarettes, or switch to EHCSS-K3, EHCSS-K6,
or Lark1 cigarettes, or to no-smoking (Tricker et al., 2012c). The
study was conducted in Osaka, Japan. The primary objective of
the study was to compare exposure to CO between the study
groups on Day 8. CO exposure was signiﬁcantly lower in the EHCSS
groups than in the Lark1 group at Day 8 (p < 0.001). The mean de-
creases from baseline (Day 0) to Day 8 were statistically signiﬁcant
(p 6 0.05) for all biomarkers of exposure to the selected HPHC
including CO, and mutagenic material in urine in the EHCSS-K3
(range: 9.8 ± 60.0 to 73.0 ± 13.0%) and EHCSS-K6 (range:
14.6 ± 51.8–75.6 ± 11.4%) groups. The largest reductions in
exposure to HPHC (all signiﬁcant at the p 6 0.01 level) occurred
in the no-smoking group (range: 13.7 ± 90.9 to 97.6 ± 6.5%).
In Part 6 of this series of papers, a 6 day randomized, controlled,
open-label, parallel-group, single-center study design was used to
compare biomarkers of exposure to twelve selected HPHC in ciga-
rette smoke (Table 2) and serum Clara cell 16-kDa protein, an indi-
cator of lung epithelial injury, in 102 male and female Japanese
subjects smoking the M4JM cigarette at baseline who were ran-
domized to continue smoking M4JM, or switch to smoking
EHCSS-K6M, or switch to Lark1M, or to no-smoking (Tricker et al.,
2012d). The study was also conducted in Osaka, Japan, and was de-
signed to investigate the effect of menthol in the EHCSS-K6M ciga-
rette. The primary objective of the study was to compare exposure
to CO between the study groups on Day 5/6. Exposure to CO was
signiﬁcantly reduced on Days 5/6 for the EHCSS-K6M group than
for both M4JM and Lark1M groups (p < 0.001). The mean decreases
from baseline (Days 1/0) to Day 5/6 were statistically signiﬁcant
(p 6 0.05) for exposure to CO, most biomarkers of exposure and
excretion of mutagenic material in urine in the EHCSS-K6M group
(12.3 ± 34.9 to 83.4 ± 9.7%). The largest mean reductions
(p 6 0.05) in exposure to CO, most biomarkers of exposure to HPHC
and excretion of mutagenic material in urine occurred in the no-smoking group (1.4 ± 41.0 to 93.6 ± 9.0%). Serum concentra-
tions of Clara cell 16-kDa protein were not signiﬁcantly changed
in all groups, compared to baseline.
In Part 7 of this series of papers, a one month randomized, open-
label, ambulatory, controlled clinical study to compare biomarkers
of exposure to ten selected HPHC in cigarette smoke (Table 2) in
316 male and female Polish subjects who smoked their usual brand
of CC at baseline and were randomized to either continue smoking
their own brand of cigarettes or switch to EHCSS-K6 (Martin Leroy
et al., 2012). The study was conducted in Warsaw, Poland. The
study was intended to assess whether changes in exposure to
HPHC determined in the above short-term clinical conﬁnement
studies are representative of reductions in subjects switching to
smoke the EHCSS-K6 cigarette under real-life conditions. Bio-
marker assessments were performed at baseline (Day 0) and at
various time points until completion of the study (Day 35). The pri-
mary objective of the study was to compare high-sensitivity C-
reactive protein (hs-CRP) and white blood cell (WBC) counts after
one month (Day 35). Within-group comparisons showed reduc-
tions in median serum hs-CRP from baseline (1.37 mg/l) to the
end of study (1.11 mg/l) for the EHCSS-K6 study group and from
1.18 to 0.85 mg/l in the CC group. Mean WBC counts decreased
from 7.09 ± 1.73 G/l to 6.90 ± 1.64 G/l and 7.00 ± 1.63 G/l to
6.94 ± 1.60 G/l in the EHCSS-K6 and CC groups, respectively. All
biomarkers of exposure to HPHC were decreased in the EHCSS-
K6 group at Day 35, although increases in cigarette consumption
were observed. However, none of the reductions in biomarkers of
exposure between the EHCSS-K6 and CC groups was signiﬁcant.6. Nicotine bridging and population level modeling
In Part 8 of this series of papers (Urban et al., 2012), the concept
of ‘nicotine bridging’ was used to model additional HPHC uptake
distributions based on nicotine uptake distributions obtained for
mainstream smoke chemistry analysis of 2 CC and the EHCSS-K6
using the ISO regimen and 15 additional experimental machine-
smoking regimens reﬂecting HPB (Part 2; Zenzen et al., 2012)
and a clinical evaluation (Part 3; Tricker et al., 2012a). Modeling
HPHC uptake proportional to nicotine uptake distributions serves
as a means to assess exposure to HPHC since biomarkers of expo-
sure to nicotine can be directly measured in clinical/population-
based studies and nicotine uptake distributions calculated (Urban
et al., 2012). It is assumed that exposure distributions for other
HPHC for which biomarkers of exposure are not available also
show quantitative retention similar to the pulmonary deposition
and retention of nicotine, which is almost (i.e., 90–100%) complete
(Armitage et al., 2004; Baker and Dixon, 2006). Consequently, dif-
ferences in exposure to HPHC from different cigarette designs, e.g.,
in smokers of CC and smokers switching to the EHCSS, can be esti-
mated based on distribution analysis of clinically determined nic-
otine uptake and smoke chemistry data. Furthermore, reduced
exposure assessment can be extended by evaluation of similarity
of the CC (‘test’) nicotine uptake distribution in a clinical setting
(‘smoker level’) with the population-based nicotine uptake distri-
bution of similar ISO tar yield (‘reference’) cigarettes of the same
geographical region (‘population level’). A criterion for similarity
(test population/reference population) used was the 90% conﬁ-
dence interval of the median nicotine uptake (ratio of medians of
test/reference), which should lie within the interval of 0.8–1.25.
This evaluation addresses some concerns related to the applicabil-
ity of results obtained in a clinical study population to a larger
population.
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As described in the IOM Report (Institute of Medicine, 2001),
population harm (morbidity and mortality associated with tobacco
use) is a function of toxicity of the product (per use), the intensity
of its use (per user), and the prevalence of use. These product test-
ing components have been further extended by the FSPTCA to in-
clude that a MRTP will signiﬁcantly reduce the risk of tobacco-
related disease to individual users, and beneﬁt the health of the
population as a whole, taking into account both current and future
users of tobacco products (Family Smoking Prevention and Tobacco
Control Act, 2009; Institute of Medicine, 2012). It is clear that
‘prevalence of use’ and ‘beneﬁt the health of the population as a
whole’ are requirements at the ‘population level’ that require a
product assessment strategy much beyond that described in this
series of eight papers. Similarly, a recent review by Hatsukami
et al. (2012) on ‘Tobacco and nicotine product testing’ suggests that
further studies, in particular on population effects, may be needed
to inform a decision on reduced substance exposure. Such evidence
should include:
(i) Clinical evaluations using comparator products that are rep-
resentative of a market sample of different CC. The HPHC
yields of the MRTP should ideally, with the exception of nic-
otine, be below the HPHC yields in CC when expressed on a
per mg nicotine basis. Special analytical techniques may be
required to identify whether novel compounds are present
in the smoke aerosol compared to CC (Knorr et al., 2011).
(ii) Short-term clinical trials that are representative of ‘actual
use’, i.e., no limitations in smoking rate, and subjects should
be allowed to smoke their preferred brand in the CC group.
(iii) Assessment of consumer acceptability and perceptions of
the MRTP.
(iv) Determination of the population exposure of the MRTP as
actually used by consumers.
(v) Determination of whether the reduction in exposure from a
MRTP vs. CC is ‘substantial’ and supports a potential for
reduced risk. A useful approach to this could be the risk
and exposure reduction attained with the use of MRTP com-
pared to smoking cessation (or cessation products) in clini-
cal studies (Institute of Medicine, 2012), and
(vi) Estimation of the potential to reduce exposure to HPHC
using modeling approaches such as HPHC-to-nicotine corre-
lations (Zenzen et al., 2012) and ‘nicotine bridging’ (Urban
et al. 2012).
8. Summary
Developing MRTPs has been one of PMI’s top priorities for many
years. The challenge posed to us, and others in this area, is to re-
duce consumer exposure to HPHC while assuring consumer accep-
tance of products that achieve those reductions. With the testing
approach presented in this series of papers we present one of the
most comprehensive evaluations of a potential reduced exposure
product performed to date. The evaluation includes investigating
the MRTP in the laboratory under an extensive range of conditions,
controlled clinical studies in different populations, and an ex-
tended clinical evaluation of biomarkers of exposure and effect
for a one month period under conditions of actual use. In addition,
a modeling approach is used to estimate exposure HPHC for which
biomarkers of exposure are not available, and by comparing nico-
tine uptake distributions on a population level. This provides a
three-level heuristic exposure assessment of the MRTP at the
‘product’, ‘smoker’, and ‘population level’.On the product level, both an MRTP’s aerosol and the conven-
tional cigarette smoke yields to which it is compared was gener-
ated in a way that reﬂects human smoking behavior (taking into
account, for example, data from nicotine uptake distributions from
clinical or observational studies, in order to better anticipate the
exposures that would result from actual product use). Smoking
the same MRTP and representative CCs under multiple machine-
smoking conditions to determine the HPHC/nicotine ratios over a
range of nicotine yields is a novel concept to understand the im-
pact on aerosol composition due to high intra- and inter-smoker
variability of nicotine uptake.
We have also studied the performance of the MRTP in a series of
clinical studies which compare the use of the product in several
different populations. One of the concerns raised by tobacco and
public health scientists (Hatsukami et al., 2012) has been that
the subpopulation of individuals who may elect to use such prod-
ucts may have speciﬁc smoking characteristics which need to be
represented in evaluation process. Consequently, populations from
three different countries were evaluated using comparator ciga-
rettes with similar ISO tar and nicotine deliveries to the MRTP. A
series of clinical studies have been performed which were designed
to measure exposure to selected HPHC in a highly controlled envi-
ronment over a period of several days (Parts 3–6; Tricker et al.,
2012a,b,c,d). Such studies are considered appropriate to examine
human exposure occurring under natural conditions (Hatsukami
et al., 2005). To investigate whether such studies represent real-
world patterns of product use, we also investigated biomarkers
of exposure and effect in smokers for a one month period under
conditions of actual use (Part 7; Martin Leroy et al., 2012).
We have used a panel of biomarkers of exposure to selected
HPHC based on the availability of validated analytical methods of
determination; however, we realize that some limitations may ap-
ply to the selected panel of biomarkers of exposure. The speciﬁcity
of AAMA and GAMA as biomarkers of exposure to acrylamide in
cigarette smoke is limited due to widespread exposure to acrylam-
ide in heat-treated carbohydrate rich foods (Bjellaas et al., 2007).
Similarly, the ubiquitous occurrence of acrolein in the environment
and endogenous formation during lipid peroxidation (Stevens and
Meier, 2008) may limit the usefulness of 3-HPMA to assess changes
in tobacco smoke-related exposure to acrolein. Similarly, the spec-
iﬁcity of 1-OHP as a surrogate marker for exposure to polycyclic
aromatic hydrocarbons (PAH) in cigarette smoke is limited due to
multiple environmental sources of pyrene (Strickland et al., 1996).
Nevertheless, 1-OHP has proved to be a suitable biomarker of
exposure to PAH in studies investigating smoking of either EHCSS
or conventional cigarettes, and non-smoking, under controlled
conditions (Feng et al., 2006). Some doubt also exists as to the
speciﬁcity of HMPMA as a biomarker of exposure to crotonalde-
hyde (Hecht et al., 2001). Several known metabolites which have
been proposed as biomarkers of exposure to 1,3-butadiene lack
sensitivity at low levels of exposure (van Sittert et al., 2000), while
many known metabolites of benzene, e.g., trans,trans-muconic acid
(t,t-MA), are either non-speciﬁc to benzene exposure (Medeiros
et al., 1997) or are also present in the diet (Boogaard and van Sitt-
ert, 1996; Ruppert et al., 1997). The mainstream smoke constitu-
ents responsible for the excretion of mutagenic material in urine
are also currently unknown. As a consequence, we have only used
the Salmonella YG1024 tester strain which is known to be sensitive
to the mutagenic activity of aromatic amino, hydroxylamino, and
nitro compounds (Einistö et al., 1990), but is unable to detect the
mutagenic activity of other classes of cigarette smoke mutagens
excreted in urine.
Our current use of nicotine equivalent excretion in urine, the
best available method to estimate total nicotine exposure, has also
allowed the determination of effective HPHC-to-nicotine regres-
sions for each of the HPHC determined using biomarkers of expo-
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ered to be critical by the public health community (Burns, 2006;
Burns et al., 2008; World Health Organization, 2008) and has not
been adequately addressed in previous studies. The presented ser-
ies of papers provide clear evidence that this goal can be achieved
for many smoke toxicants.
The ﬁnal paper in this series (Part 8; Urban et al., 2012) offers an
approach to bridge from laboratory and clinical studies performed
under controlled conditions to estimate exposure at the population
level.
Although regulatory guidance on the assessment of MRTPs
should soon become available in the US (Family Smoking Preven-
tion and Tobacco Control Act, 2009), we present our learnings from
reduced exposure testing dating back to before the FSPTCA was en-
acted. We believe that the elements we present are a step towards
a reasonable assessment strategy, but additional insight, in partic-
ular for the assessment of population level exposure, needs to be
gained from future assessments.9. Conﬂict of Interest statement
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